

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Referring Patients for Nuclear Medicine Procedures in Greater Glasgow and Clyde

Introduction

The Ionising Radiation (Medical Exposure) Regulations IR(ME)R] 2017 make it necessary for all investigations using ionising radiation to be justified on an individual patient basis. To meet this requirement, the Nuclear Medicine service have produced the following table of referral criteria which, if met, would justify a nuclear medicine procedure under most circumstances. These are taken from professional body guidelines including:

- British Nuclear Medicine Society
www.bnms.org.uk
- European Association of Nuclear Medicine
www.eanm.org
- Society of Nuclear Medicine
www.snm.org
- Royal College of Radiologists, in particular their Making the Best use of Clinical Radiology which can be accessed via staffnet at
www.irefer.scot.nhs.uk

Follow the link 'Accessing iRefer' click on the 'iRefer' link under the NHS Scotland heading and use the green' 'Log in automatically' button.

Referring Patients

Referrals are accepted from any hospital doctor who is, or is acting on behalf of, a Consultant or any General Practitioner (GP referrals are only accepted in limited situations, **not** including PETCT) or an approved non-medical referrer. The name of the Consultant or General Practitioner must be clearly stated on the request.

Clinical Information

Under the IRMER regulations it is essential that requests for nuclear medicine procedures contain sufficient clinical detail to allow the justification and authorisation of the procedure by Nuclear Medicine staff. Part of the regulations clearly states the responsibility of the referrer..."*The referrer must supply the practitioner with sufficient medical data (such as previous diagnostic information or medical records) relevant to the exposure requested by the referrer to enable the practitioner to decide whether there is a sufficient net benefit.*" Please note that the referrer remains responsible for the referral even if the task is delegated to another hospital doctor acting on their behalf. The practitioner for a Nuclear Medicine procedure will always be a clinician holding a Practitioner's license issued by ARSAC.

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	1 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Patient Information on Request

The following information about the patient is required as a minimum:

- Patient's surname
- Patient's forename
- Date of Birth
- Address
- CHI Number
- Examination requested
- **Sufficient clinical information relevant to justify the medical exposure requested**
- **Indication of pregnancy, LMP and breast feeding as appropriate**
- **In the case of pregnancy the referrer should confirm that a risk benefit discussion with the patient has taken place**
- Indication of known potential medical complications associated with examination requested e.g. allergy, renal function (for CT contrast)
- Signature of referrer (this may be physical or in terms of an electronically validated request)
- NAME of referrer
- Date of referral
- Name of consultant
- Hospital / Ward / Department / GP surgery
- Research projects should be clearly identified

Please be patient if Nuclear Medicine staff contact you to ask for more information.

Radiation Protection of Other People

Nuclear Medicine investigations are different from other radiological investigations because the patients themselves become radioactive and may therefore pose a radiation risk to others. Please pay particular attention to any instruction sent back with the patient, with particular regard to whether urine and blood samples can be taken, bearing in mind these may both be radioactive. Occasionally, investigations or treatments cannot be carried out because of the patient's family circumstances.

Radiation Dose to the Patient, Pregnancy and Breastfeeding/Chestfeeding

The list of investigations following contains information about the radiation dose received (in mSv) by the patient from the procedure and this must be borne in mind when considering the suitability of using a nuclear medicine procedure. As a guide, the natural background radiation dose received by any person is about 2.5 mSv per annum. In the pregnant patient there is also a radiation dose to the foetus and this must be strictly limited and a referrer should have a risk benefit discussion with the patient prior to the referral. Furthermore, many radiopharmaceuticals appear in breast milk, so the breast-fed infant would receive a radiation dose. **For these reasons the fact or possibility of pregnancy or breastfeeding must be clearly stated in the request for all individuals of childbearing potential in the age range 12-55 years old.**

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	2 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Supplementary Drugs

In addition, some investigations require the administration of other, non-radioactive pharmaceuticals as an essential part of the test. These are specified in *italics* after the relevant referral criteria. Your request for an investigation will be taken as implying agreement to the administration of the specified supplementary drug (this includes the administration of saline). If you are unhappy about your patient being given these drugs or you feel they are contraindicated this must be **clearly** stated in the request. Details of the dosages used are available in the appendix.

SPECT-CT

Nuclear medicine is a functional imaging modality it does however have poorer resolution than many other types of imaging. Most nuclear medicine departments now have access to a low dose CT along with the nuclear medicine equipment and this can be used in SPECT-CT to allow anatomical localisation and in some cases characterisation of lesions. Some investigations have this undertaken in all cases (the use of SPECT-CT is indicated on the table), in others experienced staff within nuclear medicine will decide whether SPECT-CT would be beneficial. The dose information in the table below excludes the CT element as this will be variable. All PET investigations involve a CT exposure as standard.

PET-CT

Like general nuclear medicine PET-CT is a functional imaging modality and All PET investigations involve a CT exposure as standard.

Less Common Procedures

Certain Investigations are not carried out by all Nuclear Medicine Departments. If necessary the request may be sent to another site. There may be other procedures which fall into the category of research investigations and the Practitioner should be contacted.

Please note that if a Trakcare or Ordercomms referral is made and then cancelled by the referrer the department **MUST** be contacted (see details below) to cancel the request, as Trakcare does not inform the imaging department of the cancellation and there is a potential for a radiation incident.

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	3 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Contact Points

General Nuclear Medicine

NE Sector (dealing with requests from)
Glasgow Royal Infirmary
Stobhill Hospital
Inverclyde Royal Hospital
Lightburn Hospital
Dental Hospital

Email

ggc.nuclearmedicine.nesector@nhs.scot

Telephone

0141 242 (2)9885

South Sector (dealing with requests from)
Queen Elizabeth University Hospital
Institute of Neurological Sciences
Victoria Hospital
Royal Alexandra Hospital
Dykebar Hospital

ggc.southglasgow.nuclearmedicine@nhs.scot

0141 452 (8)3659

NW Sector (dealing with requests from)
Gartnavel General Hospital including
Beatson Oncology Centre
Vale of Leven Hospital
Drumchapel Hospital

ggc.nuclearmedicine.gartnavel@nhs.scot

0141 301 (5)7900

Specialised Departments

Nuclear Cardiology – North Glasgow	0141 211 (5)8500
PET	0141 301 (5)7800
Paediatrics	0141 452 (8)3688

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	4 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Nuclear Medicine Investigation Groups

Contents

Nuclear Medicine Investigation Groups	5
Contents	5
Bone Imaging	6
Brain Imaging	7
Specialist Brain Imaging - The Institute of Neurological Sciences on the QEUH campus is a specialist centre and as such has specific referral criteria – please refer to this section for Specialist Brain Imaging.	7
Cardiac Imaging	8
Eye Imaging	8
Gastro-Intestinal Imaging & Investigation	9
Haematological Imaging & Investigation	9
Hepatobiliary Imaging	10
Infection, Inflammation Imaging & Investigation	11
Lung Imaging	12
Lymphatic Imaging & Investigation	12
Renal Imaging & Investigation	13
Salivary Imaging	13
Thyroid & Parathyroid Imaging & Investigation	14
Therapeutic	15
Tumour Imaging	15
PET-CT Imaging	16
Investigation of Lung Cancer, including NSCLC and characterisation of solitary pulmonary nodule	16
Appendix – Pharmaceuticals used with doses	17

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	5 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Referral Criteria

* dose received from ARSAC diagnostic reference level (DRL)

1. SNM Guidelines
2. BNMS Guidelines (including EANM)
3. RCR Guidelines

Bone Imaging

Isotope bone imaging with ^{99m}Tc HDP is highly sensitive for osteoblastic activity but has poor specificity.

In lytic disease (e.g. myeloma, RCC) ^{99m}Tc HDP imaging can give misleading information.

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of neoplasia ₁	^{99m}Tc -HDP	2.9
Staging or re-staging ₂	^{99m}Tc -HDP	2.9
assessment of bone pain with known or suspected malignancy ₂	^{99m}Tc -HDP	2.9
increased tumour marker levels (e.g. PSA)	^{99m}Tc -HDP	2.9
monitoring disease progression and response to chemo or radiotherapy ₂	^{99m}Tc -HDP	2.9
Investigation of imaging abnormality	^{99m}Tc -HDP	2.9
Investigation of bone pain/loosening/infection post joint replacement (> 1 year post-op)	^{99m}Tc -HDP	2.9
Investigation of Paget's disease	^{99m}Tc -HDP	3
Investigation of stress fracture, shin splints ₃	^{99m}Tc -HDP	3
Investigation of mandibular disorders (Condylar disease)	^{99m}Tc -HDP	5
Investigation of bony pain which is otherwise unexplained ₁	^{99m}Tc -HDP	2.9
Investigation of osteomyelitis ₁	^{99m}Tc -HDP	2.9
Investigation of arthritides ₁	^{99m}Tc -HDP	2.9
Assessment of x-ray abnormality	^{99m}Tc -HDP	2.9
Investigation of hypercalcaemia	^{99m}Tc -HDP	2.9
Investigation of low back pain	^{99m}Tc -HDP	2.9
Investigation of occult fracture ₁	^{99m}Tc -HDP	2.9
Distribution of osteoblastic activity prior to therapy ₁	^{99m}Tc -HDP	2.9
Investigation of distribution of osteoporotic fractures	^{99m}Tc -HDP	2.9
Investigation of osteoid osteoma	^{99m}Tc -HDP	2.9
Investigation of complex regional pain syndrome CRPS (RSD) ₁	^{99m}Tc -HDP	2.9
Investigation of hypocalcaemia (osteomalacia) ₃	^{99m}Tc -HDP	2.9
Investigation of bone infarcts ₁	^{99m}Tc -HDP	2.9
Investigation of bone graft viability ₁	^{99m}Tc -HDP	2.9

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	6 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Brain Imaging

The following procedures can be undertaken at general nuclear medicine departments within GGC. SPECT-CT (low dose CT) is often used in these investigations

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of dementia _{1,3}	^{99m} Tc-HMPAO	7
Investigation of regional cerebral blood flow _{1,3}	^{99m} Tc-HMPAO	7
Investigation of movement disorder, ET, Drug-induced or vascular parkinsonism or a parkinsonian syndrome.	¹²³ I-DaTSCAN <i>Potassium iodate/iodide</i>	4.6
Dementia with Lewy Bodies	¹²³ I-DaTSCAN <i>Potassium iodate/iodide</i>	4.6
Cardiac sympathetic innervation imaging in movement disorders (Parkinson's disease etc.) /Lewy body dementia	¹²³ I-mIBG <i>Potassium iodate/iodide</i>	5

Specialist Brain Imaging - The Institute of Neurological Sciences on the QEUH campus is a specialist centre and as such has specific referral criteria – please refer to this section for Specialist Brain Imaging.

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Usage as above plus evaluation of encephalitis ₃ cerebrovascular disease ₂ , traumatic brain injury ₂ ,suspected inflammation ₂ Determination of brain death ₂	^{99m} Tc-HMPAO	7
Investigation of epilepsy (ictal and inter-ictal) _{1,3}	^{99m} Tc-HMPAO	7
Investigation of tumour viability including differential diagnosis of brain tumours (including malignant versus benign disease), determination of malignancy grade of gliomas, differential diagnosis of pseudoprogression and radiation necrosis (including tumour progression vs radiation necrosis) Selection of biopsy site	²⁰¹ Tl-chloride	14
Tumour delineation for therapy planning Follow-up of primary brain tumours and malignant transformation Differential diagnosis of Toxoplasmosis and Lymphoma in immunocompromised patients		
Differential diagnosis of meningioma vs other brain masses Localisation of brain tumours (usually meningioma) Follow-up of meningiomas.	^{99m} Tc-Tekrotyd	3.7
Differential diagnosis of metastases expressing somatostatin receptors		

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	7 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Cardiac Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Diagnosis of coronary artery disease _{1,2} presence _{1,2} location (coronary territory) _{1,2} Extent (number of vascular territories) _{1,2}		
Assessment of the degree of coronary stenosis and impact on regional perfusion ₁		
Myocardial viability assessment _{1,2} Ischaemia vs. scar ₁ predict improvement in function following revascularization _{1,2}	^{99m} Tc-tetrofosmin or ²⁰¹ Tl-chloride Adenosine Dobutamine Regadenoson	1-day: 3.4 / 4 (Stress/Rest) 2-day: 1.7 / 6 (Stress/Rest) 8.4
Risk assessment (prognosis) in patients _{1,2} post myocardial infarction ₁ pre-operative for major surgery who may be at risk for coronary events ₁		
Monitoring treatment effect ₁ after coronary revascularization _{1,2} Medical therapy for congestive failure or angina ₁ Lifestyle modification ₁		
Pre cardiac transplant assessment		
Post cardiac transplant assessment		
Assessment of congenital cardiac abnormalities		
Assessment of arrhythmias		
Assessment of right ventricular dysplasia		
Assessment of patients with Syndrome X ₂		
Assessment of cardiac ejection fraction Regional wall motion, ventricular volumes and stroke volume ratios	^{99m} Tc-normal erythrocytes Pyrophosphate	5.6
Monitoring cardiac ejection fraction following administration of cardiotoxic drugs	^{99m} Tc-normal erythrocytes Pyrophosphate	5.6
Investigation of cardiac amyloid in patients with known or suspected amyloidosis	^{99m} Tc-DPD	5.6

Eye Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of lacrimal drainage	^{99m} Tc-pertechnetate ^{99m} Tc-colloid	0.05 0.04

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	8 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Gastro-Intestinal Imaging & Investigation

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of gastric emptying ¹ Patients with suspected gastroparesis, nausea, vomiting, upper abdominal bloating or chronic aspiration		
	^{99m} Tc-solid meal	0.3
	¹¹¹ In-DTPA or ^{99m} Tc colloid	3.8 0.9
Investigation of oesophageal transit and reflux ¹	^{99m} Tc-solid meal	0.9
Investigation of Meckel's diverticulum as a source of unexplained GI bleeding ^{1,3}	^{99m} Tc-pertechnetate <i>Cimetidine (GRI, RHSC)</i>	5
Investigation of Gastrointestinal bleeding ^{1,3}	^{99m} Tc-normal erythrocytes <i>Pyrophosphate</i>	2.8
Investigation of bile salt absorption	⁷⁵ Se-SeHCAT	0.3

Haematological Imaging & Investigation

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Measurement of blood volume (e.g. in polycythaemia)	¹²⁵ I-HSA <i>Potassium iodate/iodide</i> and ¹¹¹ In-normal erythrocytes	0.04 2.8
Investigation of splenic function in patients with thrombocytopenia ¹	^{99m} Tc-denatured red cells	2
To check if mass is functioning splenic tissue and or/ assess localisation of spleen tissue ¹	^{99m} Tc-denatured red cells or ^{99m} Tc-colloid ± SPECT-CT	0.2 or 1.8

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	9 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Hepatobiliary Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Evaluation of suspected cholecystitis 1	^{99m}Tc -IDA	2.4
Evaluation of chronic biliary tract disorders 1	^{99m}Tc -IDA	2.4
Evaluation of common bile duct obstruction 1	^{99m}Tc -IDA	2.4
Detection of bile extravasation 1	^{99m}Tc -IDA	2.4
Evaluation of abnormalities of biliary tree 1	^{99m}Tc -IDA	2.4
Investigation of pain post cholecystectomy	^{99m}Tc -IDA	2.4
Investigation of pain in suspected biliary hypertension	^{99m}Tc -IDA	2.4
Investigation of gall bladder kinetics	^{99m}Tc -IDA <i>Fatty meal stimulated (Calogen)</i>	2.4
Investigation of bile duct kinetics	^{99m}Tc -IDA	2.4

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	10 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Infection, Inflammation Imaging & Investigation

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
To detect sites of infection/inflammation in patients with fever of unknown origin ¹	Labelled leucocytes are preferred Labelling can be achieved with: ^{111}In -leucocytes or $^{99\text{m}}\text{Tc}$ -exametazime leucocytes	7.2
To localize an unknown source of sepsis and to detect additional site(s) of infection in patients with persistent or recurrent fever and a known infection site 1(any renal or bone or any chronic infection)		2.2
To detect and follow-up osteomyelitis primarily when there is existing bone pathology such as infected joint prostheses, non-united fractures or sites of metallic hardware from prior bone surgery ¹		
To detect osteomyelitis in diabetic patients when degenerative or traumatic changes, neuropathic osteoarthropathy or prior osteomyelitis have caused increased bone remodelling ¹		
To detect osteomyelitis involving the skull in postoperative patients and for follow-up of therapy ¹		
To detect mycotic aneurysms, vascular graft and shunt / fistula infections ¹		
In cases of osteomyelitis when there has been orthopaedic intervention such as infected joint prostheses, or sites of metallic hardware from prior bone surgery ¹	^{111}In -Leucocytes or $^{99\text{m}}\text{Tc}$ -exametazime leucocytes \pm $^{99\text{m}}\text{Tc}$ -colloid (for marrow delineation)	7.2 or 2.2 \pm 3.6
To detect site(s) and extent of inflammatory bowel disease ¹	$^{99\text{m}}\text{Tc}$ -exametazime leucocytes	2.2
To detect site(s) and extent of Crohn's disease ¹	$^{99\text{m}}\text{Tc}$ -exametazime leucocytes	2.2
To survey for site(s) of abscess or infection in a febrile post-op patient without localizing signs or symptoms. Fluid collections, ileus, bowel gas and/or fluid, and healing wounds reduce the specificity of CT and ultrasound ¹	^{111}In -leucocytes or $^{99\text{m}}\text{Tc}$ -exametazime leucocytes	7.2 or 2.2
Diagnosing osteomyelitis and/or disk space infection. Ga-67 is preferred over labelled leukocytes for disk space infection ¹	^{67}Ga -citrate	15
Evaluation and follow-up of Malignant Otis Externa	^{67}Ga -citrate	15

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	11 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Lung Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of acute PTE _{1,2}	<u>Perfusion :</u> ^{99m} Tc-MAA <u>Ventilation :</u> ^{81m} Kr or ^{99m} Tc-Technegas	2 0.2 0.6
Monitor changes in perfusion after PTE ₂		
Investigation and follow up of PTE		
Investigation of right ->left intracardiac shunts ₁		
Investigation of chronic lung disease		
Post pneumonectomy assessment	^{99m} Tc-MAA	2
Preoperative perfusion assessment		

Lymphatic Imaging & Investigation

Sentinel node investigation for some cancers require specialist ARSAC approval and the individual departments should be contacted directly about such investigations, e.g. head and neck, penile, vulval...
Doses given for same day / next day procedure.

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Sentinel node localisation melanoma patients	^{99m} Tc-colloid	0.09/0.18
Investigation of poor lymph drainage	^{99m} Tc-colloid	0.09
Sentinel node localisation breast patients	^{99m} Tc-colloid	0.02/0.08
Sentinel node localisation penile cancer	^{99m} Tc-colloid	0.27/0.53
Sentinel node localisation head and neck	^{99m} Tc-colloid	0.09/0.18

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	12 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Renal Imaging & Investigation

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Assessment of split renal function or function of one or more moieties ₂	^{99m} Tc-MAG3 or ^{99m} Tc-DMSA	0.7 0.7
Assessment of obstruction	^{99m} Tc-MAG3	0.7
Dilation of collecting system ₂	<i>Frusemide</i>	
Suspected PUJ obstruction ₂		
Post surgical evaluation of a previously obstructed system ₂		
Indirect micturating cystogram for vesico-ureteric reflux ₂	^{99m} Tc-MAG3	0.7
Assessment of kidney and scarring ₂	^{99m} Tc-DMSA	0.7
In acute UTI ₂		
Post UTI infection ₂		
Assessment of horseshoe or ectopic kidney ₂	^{99m} Tc-DMSA	0.7
Localisation of poorly functioning kidney ₂	^{99m} Tc-DMSA	0.7
Assessment of kidney function in presence of an abdominal mass ₂	^{99m} Tc-DMSA	0.7
Assessment of perfusion of renal transplants	^{99m} Tc-pertechnetate	10
Assessment of kidney perfusion	^{99m} Tc-pertechnetate	4.4
Assessment of urine leak post surgery	^{99m} Tc-MAG3	0.7
Assessment of patients with nephrotic syndrome	^{99m} Tc-MAG3	0.7
Measurement of Glomerular Filtration Rate (GFR)	^{99m} Tc DTPA	0.05
Assessment of live kidney donor	^{99m} Tc-DTPA (GFR) ± ^{99m} Tc-MAG3	0.05 ± 0.7

Salivary Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of dry mouth ₃	^{99m} Tc-pertechnetate	0.5

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	13 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Thyroid & Parathyroid Imaging & Investigation

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Assessment of functionality and structure of thyroid nodules _{1,2}	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
Assessment of goitre including hyperthyroid goitre ₂	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
Assessment of uptake function prior to radio-iodine therapy _{1,2}	¹²³ I or ^{99m} Tc-pertechnetate or I131 ± SPECT-CT	6.1 or 1 or 20
To locate ectopic thyroid tissue (i.e. lingual) or determine whether a suspected "thyroglossal duct cyst" is the only functioning thyroid tissue present _{1,2}	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
To assist in evaluation of congenital hypothyroidism ₁	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
To evaluate a neck mass. Radionuclide scintigraphy may be helpful to confirm that the mass is functioning thyroid tissue ₁	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
To investigate retro-sternal goiter or sub-sternal mass	¹²³ I	6.1
To differentiate thyroiditis (i.e. subacute or silent) and factitious hyperthyroidism from Graves' disease and other forms of hyperthyroidism _{1,2}	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
To investigate the suspected misuse of thyroxine / triiodothyronine	¹²³ I or ^{99m} Tc-pertechnetate	6.1 or 1
Thyroid uptake studies in the investigation of thyroid disease (uptake counter) ₁	¹²³ I or ^{99m} Tc-pertechnetate	0.6 or 0.5
Whole-body ¹²³ I / ¹³¹ I imaging for thyroid metastases ₁	I123 or I131 ± SPECT-CT	8 or 20
Investigation of thyroid binding defects	¹²³ I Perchlorate (for discharge)	6.1
Investigation of thyroid cancers ₁	¹²³ I ¹³¹ I ± SPECT-CT	7.8 34
Investigation of hyperparathyroidism ₁	^{99m} Tc-sestamibi + ¹²³ I	8.1
To localize tissue prior to surgery or in patients with persistent or recurrent disease	+ SPECT-CT	6.1
Differentiation of type of amiodarone induced thyrotoxicosis	^{99m} Tc-sestamibi	2

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	14 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	 NHS Greater Glasgow and Clyde
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

Therapeutic

Please note these therapies have very specific radiation protection needs and therefore are only performed on a limited number of specific sites.

Investigation and clinical history	Radio-pharm / Pharmaceutical
Thyrotoxicosis	^{131}I
Toxic diffuse goitre ²	^{131}I
Uni-nodular toxic goitre (toxic adenoma) ²	^{131}I
Multi-nodular toxic goitre (multifocal autonomy) ²	^{131}I
Nodular goitre – non-toxic	^{131}I
Thyroid cancer ²	^{131}I
Neuroendocrine tumours ²	^{131}I –mIBG <i>Potassium iodate/iodide</i>
Bone metastases (palliative pain relief) ^{1,2}	^{89}Sr or ^{186}Re -HEDP
Treatment of Polycythaemia rubra vera and essential thrombocythaemia	^{32}P
Treatment of arthritic conditions / synovitis ²	^{90}Y
Treatment of cystic brain tumours	^{90}Y
Treatment for bone pain in prostate cancer	^{223}Ra -chloride
Treatment for lymphoma	^{90}Y -Zevalin
Treatment for carcinoid	^{90}Y -peptides
Treatment for carcinoid	^{177}Lu -peptides <i>Amino acid solution</i>

Tumour Imaging

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigations of neuroendocrine tumours	^{123}I -mIBG SPECT-CT <i>Potassium iodate/iodide</i>	5.2
Investigation of somatostatin producing tumours and neuroendocrine tumours	$^{99\text{m}}\text{Tc}$ -Tektrotyd SPECT-CT	3.7
Thyroid cancers – see Thyroid Investigations		
Investigation of active tumour (brain)	^{201}Tl \pm SPECT-CT	14

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	15 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Q-Pulse Database	DIAIMA	
Document Number	NM-GGC-PROC-006	
Document Title	Nuclear Medicine Referral Criteria	

PET-CT Imaging

PET/CT in Scotland is a national service and as such, the referral criteria have been produced by the Scottish PET Advisory Board: [PET-CT Guidelines – Scottish Clinical Imaging Network \(nhs.scot\)](#)
 (Note all scans include CT with a dose of up to 8 mSv. In most cases administered activity, and therefore Dose, is based on patient weight.)

Investigation and clinical history	Radio-pharm / Pharmaceutical	Dose mSv*
Investigation of Lung Cancer, including NSCLC and characterisation of solitary pulmonary nodule	¹⁸ F FDG	7.6
Investigation of Lymphoma, HD and NHL	¹⁸ F FDG	7.6
Investigation of Colorectal Cancer	¹⁸ F FDG	7.6
Investigation of other malignancies including cancers of testes, melanoma, gastro-oesophageal, breast, cervix, thyroid, CUP, paraneoplastic syndrome, CNS, thymus, gastrointestinal stroma, hepato-pancreatic-biliary, urological, anal and penile, myeloma, musculoskeletal, neuroendocrine, head and neck	¹⁸ F FDG	7.6
Investigation of biochemical recurrence of prostate cancer after treatment	¹⁸ F PSMA	6.2
Assessment of uptake prior to treatment with Lu-177 PSMA	¹⁸ F PSMA	6.2
Investigation of (somatostatin receptor positive) Neuroendocrine tumours	⁶⁸ Ga DOTATOC	5.8
Assessment of uptake prior to treatment with Lu-177 Dotatate	⁶⁸ Ga DOTATOC	5.8
Investigation of cardiac sarcoidosis or infection	¹⁸ F FDG	7.6
Investigation of systemic infectious or inflammatory processes: e.g vasculitis, sarcoidosis, infection, pyrexia of unknown origin	¹⁸ F FDG	7.6

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	16 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					

Appendix – Pharmaceuticals used with doses

	Dosage
Potassium iodate	2 x 85mg
Potassium iodide	2 x 65mg
Adenosine	140 mcg per kg per minute
Dobutamine	5 – 40 µg per kg per minute
Regadenoson	400 µg
Pyrophosphate	6.7 mg †
Cimetidine	Adult patients: 400mg
Furosemide	Adult patients: 40mg Paediatric patients: 1mg per kg – Maximum dose 20mg
Perchlorate	50 mg
Thyrogen	0.9 mg (daily for 2 days)
Saline	Various
Amino acid solution	1litre amino acid solution (containing 25g lysine and 25g arginine) at 250ml per hour
Omipaque Iohexol Solution (CT Contrast)	90 ml at concentration of 300 mg I/ml

†refer to sector specific documentation

Owner	Author	Revision	Active Date	Review Date	Page
Gannon (HoS), Mark	Bolster, Alison	10	17/10/2025	17/10/2028	17 of 17
This document is uncontrolled when printed. Check Revision BEFORE use!					